-
Seeing the (En)light Table 1. Enlight's offspring. Company Technology Founded Endra Inc. Photoacoustic molecular imaging 2008 Entrega Inc. Formulation technology for oral delivery of peptides and proteins …
Published on 1/19/2012
-
The Scripps Research Institute has decided that the kinds of broad deals it used to do with industry do not work anymore. Instead, the institute now hopes to forge a series of smaller, more focused collaborations with …
Published on 1/19/2012
-
AstraZeneca and Novo Nordisk have come off the sidelines to partner with Enlight Biosciences, making them the sixth and seventh pharmas currently working with Enlight to form platform companies.
Published on 1/19/2012
-
A conversation with Laurie Glimcher Table 1. Putting a spin (out) on New York City medical centers. Companies focusing on therapeutics, diagnostics or medical devices that were founded from 2009-2011 based on …
Published on 1/12/2012
-
As Laurie Glimcher was preparing to take over as dean of Weill Cornell, SciBX caught up with her to discuss research priorities for academic medical centers, the most effective models for promoting industry–academic …
Published on 1/12/2012
-
The U.K.'s Medical Research Council has partnered with AstraZeneca to make the pharma's shelved compounds available to academics investigating basic disease mechanisms. A first call for proposals is in progress.
Published on 1/5/2012
-
With 14 projects in place, the NIH's Therapeutics for Rare and Neglected Diseases program will shift its focus from finding projects to building infrastructure and advancing programs into the clinic.
Published on 12/15/2011
-
Translational Notes: TRND take two Table 1. TRND partnerships. List of NIH Therapeutics for Rare and Neglected Diseases (TRND) partnerships as of Dec. 12, 2011. Source: NIH Center for Translational Therapeutics …
Published on 12/15/2011
-
Cancer Research UK is brokering partnerships between its stable of academics and companies looking for a stake in early cancer discoveries. AstraZeneca is the charity's anchor collaborator with three projects, including…
Published on 11/17/2011
-
Alvos and Ablaris are using peptide-receptor pairs identified by MD Anderson researchers to target therapeutic payloads in cancer and obesity. The center now has provided preclinical proof-of-concept data and …
Published on 11/17/2011
-
Hands-off incubator Box 1. Incubators no more. In 2007, Pfizer Inc. and Biogen Idec Inc. created incubators that provided both space and funding for startups. The Biogen Idec Innovation Incubator funded and housed …
Published on 11/3/2011
-
Johnson & Johnson is opening a life sciences incubator in San Diego that provides no funding and receives no IP rights from its occupants, unlike now-defunct facilities started by companies such as Biogen Idec and …
Published on 11/3/2011
-
The pharma-led Quebec Consortium for Drug Discovery is providing C$1.2 million in funding for a quartet of projects that it hopes will apply unconventional, out-of-the-box thinking and lead to breakthrough research …
Published on 10/20/2011
-
Eli Lilly is rolling out its Open Innovation Drug Discovery platform to cast a wide net for finding innovative molecules from external investigators in the company's core disease focus areas. The pharma has also joined …
Published on 10/13/2011
-
After two years of funding pilot partnerships, the NIH's Therapeutics for Rare & Neglected Diseases program has announced its first round of competitively awarded projects. The awards to three biotechs and an academic …
Published on 10/13/2011
-
Translational Notes: TRNDing toward translation Table 1. TRND partnerships. List of NIH Therapeutics for Rare & Neglected Diseases (TRND) partnerships as of Oct. 6, 2011. Source: NIH Center for Translational …
Published on 10/13/2011
-
NIH's blueprint for translation Table 1. NIH Blueprint Neurotherapeutics Network awards. Indication Project description Institution Amyotrophic lateral sclerosis (ALS) Small molecule modulators of the glutamate …
Published on 9/8/2011
-
Six academic teams and Trevena Inc. have won cash grants and additional commitments for preclinical development support from the Blueprint Neurotherapeutics Network, an NIH program to fund translational development of …
Published on 9/8/2011
-
Target rich but chemistry poor, the University of Rochester Medical Center has teamed up with Temple University School of Pharmacy, which has strong chemistry capabilities but lacks targets for compound building. The …
Published on 8/25/2011
-
The Michael J. Fox Foundation for Parkinson's Research has expanded its programs to de-risk Parkinson's disease research and thereby attract investment into the space.
Published on 7/28/2011
-
Translational Notes: Rethinking mechanisms of drug discovery Box 1. Booting up the computers. Whereas David Swinney's paper in Nature Reviews Drug Discovery suggests ways to develop and use complex assays that …
Published on 7/14/2011
-
A Roche team has concluded that overreliance on simplistic, target-centered screens early in drug development may inadvertently select for compounds destined to fail in late-stage trials. The resulting high attrition …
Published on 7/14/2011
-
GlaxoSmithKline has started to ramp up its collaborations with individual researchers through its Discovery Partnerships with Academia program, while also partnering with MaRS Innovation to identify academic research in…
Published on 6/23/2011
-
Ascenion and Vesalius Biocapital aim to bridge the translational gap in Germany with Spinnovator, an initiative that will spin out publicly funded research into startups with a combination of private venture capital and…
Published on 6/16/2011
-
Translational Notes: iPS cells: Five Years Later Table 1. Methods for stem cell reprogramming. Current approaches to reprogramming somatic cells into induced pluripotent stem (iPS) cells fall into four major …
Published on 5/26/2011